on Hardman & Co Research (isin : GB00BYYW9G87)
Shield Therapeutics to Present at Hardman & Co Investor Forum
Shield Therapeutics (STX), a commercial-stage pharmaceutical firm, will participate in the Hardman & Co Investor Forum on 14 November 2024. Known for addressing iron deficiency, Shield has significantly increased physician awareness of its oral treatment, ACCRUFeR®, since its US launch in 2021. This strategy, in partnership with Viatris, has contributed to substantial sales growth.
The online Investor Forum will explore growth strategies amid recent economic changes, offering insights into how presenting companies plan to leverage market conditions for sustained growth. The event includes a Q&A session, open to all investors, and will provide an opportunity to learn about the company's strategies and progress.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Hardman & Co Research news